CHARACTERIZATION OF THE ATPASE ACTIVITY OF THE MR 170,000 TO 180,000 MEMBRANE GLYCOPROTEIN (P-GLYCOPROTEIN) ASSOCIATED WITH MULTIDRUG RESISTANCE IN K562/ADM CELLS

被引：0
|
作者：
HAMADA, H [1 ]
TSURUO, T [1 ]
机构：
[1] JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, KAMI IKEBUKURO, TOSHIMA KU, TOKYO 170, JAPAN
来源：
CANCER RESEARCH | 1988年 / 48卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4926 / 4932
页数：7
相关论文
共 50 条
  • [31] Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells
    Cai, Yujun
    Lu, Jinjian
    Miao, Zehong
    Lin, Liping
    Ding, Jian
    CANCER BIOLOGY & THERAPY, 2007, 6 (11) : 1794 - 1799
  • [32] Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells
    Han, Fang
    Liu, Guoqiang
    Sun, Caifeng
    Wei, Jienan
    CELLULAR AND MOLECULAR BIOLOGY, 2018, 64 (15) : 55 - 61
  • [33] Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells
    Gayet, L
    Dayan, G
    Barakat, S
    Labialle, S
    Michaud, M
    Cogne, S
    Mazane, A
    Coleman, AW
    Rigal, D
    Baggetto, LG
    BIOCHEMISTRY, 2005, 44 (11) : 4499 - 4509
  • [34] Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells
    Shtil, AA
    Grinchuk, TM
    Tee, L
    Mechetner, EB
    Ignatova, TN
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 17 (02) : 387 - 392
  • [35] Design and evaluation of dibenzoazepine-tetrahydroisoquinoline hybrids as potential P-glycoprotein inhibitors against multidrug resistant K562/A02 cells
    Jiang, Chunyu
    Pan, Ting
    Jiang, Yunxiang
    Zhang, Zhiyu
    Zeng, Meifeng
    Sun, Shuang
    Li, Zheng
    Wu, Yiqing
    Qiu, Jingying
    Niu, Mingshan
    Gu, Xiaoke
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 249
  • [36] Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin
    Xue, Chaojun
    Wang, Changyuan
    Liu, Qi
    Meng, Qiang
    Sun, Huijun
    Huo, Xiaokui
    Ma, Xiaodong
    Liu, Zhihao
    Ma, Xiaochi
    Peng, Jinyong
    Liu, Kexin
    TUMOR BIOLOGY, 2016, 37 (07) : 8587 - 8597
  • [37] Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells
    Tapan K. Dash
    V. Badireenath Konkimalla
    Pharmaceutical Research, 2017, 34 : 1741 - 1750
  • [38] Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells
    Dash, Tapan K.
    Konkimalla, V. Badireenath
    PHARMACEUTICAL RESEARCH, 2017, 34 (08) : 1741 - 1750
  • [39] Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro
    Ferrao, PT
    Frost, MJ
    Siah, SP
    Ashman, LK
    BLOOD, 2003, 102 (13) : 4499 - 4503
  • [40] Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells
    Ji, Bian-Sheng
    Li, Ming
    He, Ling
    PHARMAZIE, 2010, 65 (07): : 515 - 519
12345